Q-omics provides the consensus-scored CBX1P3 profile across patient tissues and cancer cell-line models. CBX1P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CBX1P3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CBX1P3 RNA expression shows 7,217 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where CBX1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX1P3 survival associations across molecular data types. CBX1P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX1P3 RNA expression–survival associations across cancer types. High CBX1P3 expression shows unfavorable associations in ACC, LUAD, BRCA and KICH, but favorable associations in ESCA and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CBX1P3 RNA expression.
This table summarizes CBX1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CBX1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX1P3 shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in BRCA and LUAD. The KIRC box plot shows higher CBX1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.194, t-test p < 0.001).
This table shows molecular features associated with CBX1P3 in patient tissues and cancer cell lines. In patient samples, CBX1P3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
